The company has a "cash cushion" for clinical development, in fact quite sizable. Missling has made clear he plans to market 2-73 independently for AD (see the "post-market approval" steps he's been outlining the past few years), which will require additional capital. He intended to do that with Rett too, but those plans unfortunately stalled. Hopefully AD has a better rate.
Everyone needs to keep in mind that biotech is a risky business; drugs aren't magic beans, and plans don't always come to fruition. Ignore the fantasy, chart, conspiracy, and other nonsense. Watch for EMA progress.
Market Data 
Markets 
AI
